Skip to main content
Review article

Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives

Tapan BehlDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh 140401, Punjab, IndiaGagandeep KaurDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh 140401, Punjab, IndiaAayush SehgalDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh 140401, Punjab, IndiaShaveta BhardwajSukhbir SinghDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh 140401, Punjab, IndiaCamelia Liana BuhașDepartment of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, RomaniaClaudia Teodora Judea PustaDepartment of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, RomaniaDiana UivaroșanDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, RomaniaMihai MunteanuDepartment of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, RomaniaSimona BungăuDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania
2021en
ABI

Abstract

Neurodegeneration is the pathological condition, in which the nervous system or neuron loses its structure, function, or both, leading to progressive degeneration or the death of neurons, and well-defined associations of tissue system, resulting in clinical manifestations. Neuroinflammation has been shown to precede neurodegeneration in several neurodegenerative diseases (NDs). No drug is yet known to delay or treat neurodegeneration. Although the etiology and potential causes of NDs remain widely indefinable, matrix metalloproteinases (MMPs) evidently have a crucial role in the progression of NDs. MMPs, a protein family of zinc (Zn2+)-containing endopeptidases, are pivotal agents that are involved in various biological and pathological processes in the central nervous system (CNS). The current review delineates the several emerging evidence demonstrating the effects of MMPs in the progression of NDs, wherein they regulate several processes, such as (neuro)inflammation, microglial activation, amyloid peptide degradation, blood brain barrier (BBB) disruption, dopaminergic apoptosis, and α-synuclein modulation, leading to neurotoxicity and neuron death. Published papers to date were searched via PubMed, MEDLINE, etc., while using selective keywords highlighted in our manuscript. We also aim to shed a light on pathophysiological effect of MMPs in the CNS and focus our attention on its detrimental and beneficial effects in NDs, with a special focus on Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), multiple sclerosis (MS), and Huntington’s disease (HD), and discussed various therapeutic strategies targeting MMPs, which could serve as potential modulators in NDs. Over time, several agents have been developed in order to overcome challenges and open up the possibilities for making selective modulators of MMPs to decipher the multifaceted functions of MMPs in NDs. There is still a greater need to explore them in clinics.

Identifiers

Citations and references

Cited by 20 references